Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People's Republic of China: a comparison with international studies

Efficacy and safety of an oral contraceptive containing ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) in three indications in the People's Republic of China: a comparison with international studies

Joachim Marr,1 Zirong Huang,2 Baoxi Wang,3 Hongyan Zhang,4 Katrin Roth1 1Bayer Pharma AG, Berlin, Germany; 2Obstetrics and Gynecology Hospital of Fudan University, Shanghai, 3Institute of Dermatology, Chinese Academy of Medical Sciences, Nanjing, Jiangsu, 4Peking University Sixth Hospital,...

Full description

Bibliographic Details
Main Authors:	Marr J, Huang Z, Wang B, Zhang H, Roth K
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-07-01
Series:	Open Access Journal of Contraception
Online Access:	http://www.dovepress.com/efficacy-and-safety-of-an-oral-contraceptive-containing-ethinylestradi-peer-reviewed-article-OAJC

Similar Items

Hormone withdrawal-associated symptoms with ethinylestradiol 20 µg/drospirenone 3 mg (24/4 regimen) versus ethinylestradiol 20 µg/desogestrel 150 µg (21/7 regimen)
by: Bitzer J, et al.
Published: (2015-05-01)

Therapeutic non-contraceptive properties of the drug containing ethinylestradiol 0.03 mg and drospirenone 3 mg
by: Natalia V Artymuk, et al.
Published: (2019-10-01)

Bleeding Pattern and Management of Unexpected Bleeding/Spotting with an Extended Regimen of a Combination of Ethinylestradiol 20 mcg and Drospirenone 3 mg
by: Bonassi Machado R, et al.
Published: (2020-03-01)

Contraceptive and therapeutic effects of drospirenone-containing hormonal antifertility agent with 24/4 dosage regimen
by: M A Gevorkian, et al.
Published: (2013-06-01)

Quality of Life in Japanese Patients with Dysmenorrhea Treated with Ethinylestradiol 20 μg/Drospirenone 3 mg in a Real-World Setting: An Observational Study
by: Momoeda M, et al.
Published: (2020-05-01)

Drospirenone/ethinyl estradiol 3 mg/20 &micro;g (24/4 day regimen): hormonal contraceptive choices &ndash; use of a fourth-generation progestin
by: Gloria Bachmann, et al.
Published: (2009-08-01)

Adherence with ethinylestradiol 20 µg/drospirenone 3 mg in a flexible extended regimen supported by the use of a digital tablet dispenser with or without acoustic alarm: an open-label, randomized, multicenter study
by: Wiegratz I, et al.
Published: (2015-01-01)

Drospirenone-containing contraception: curative and preventive aspects of use
by: A V Ledina, et al.
Published: (2015-02-01)

Efficacy and cardiovascular safety of the new estrogen-free contraceptive pill containing 4 mg drospirenone alone in a 24/4 regime
by: Santiago Palacios, et al.
Published: (2020-10-01)

Premenstrual syndrome: the effectiveness of treatment with a drospirenone-containing contraceptive
by: V. N. Prilepskaya, et al.
Published: (2015-12-01)

Efficacy and safety of drospirenone-containing microdosage combined oral contraceptive use with starting contraception
by: A R Khachaturian, et al.
Published: (2018-04-01)

Efficacy and safety of drospirenone-containing microdosage combined oral contraceptive use with starting contraception
by: A.R.Khachaturian, et al.
Published: (2018-04-01)

Efficacy and safety of a flexible extended regimen of ethinylestradiol/drospirenone for the treatment of dysmenorrhea: a multicenter, randomized, open-label, active-controlled study
by: Momoeda M, et al.
Published: (2017-05-01)

Drospirenone-containing oral contraceptives and venous thromboembolism: an analysis of the FAERS database
by: Madigan D, et al.
Published: (2018-04-01)

Benefits of using combined oral contraceptive with drospirenone in 24+4 overweight adolescents
by: I V Kuznetsova, et al.
Published: (2014-02-01)

Ethinylestradiol<sub>30μg</sub>-drospirenone and metformin: could this combination improve endothelial dysfunction in polycystic ovary syndrome?
by: Ilie Ioana, et al.
Published: (2012-06-01)

Clinical behavior of a cohort of adult women with facial acne treated with combined oral contraceptive: ethinylestradiol 20 µg/dienogest 2 mg
by: Palacio-Cardona J, et al.
Published: (2017-11-01)

Serum Hormone Levels, T Lymphocyte Subsets, and Achievement of Pregnancies in Patients with Premature Ovarian Insufficiency following Administration of Ethinylestradiol/Drospirenone
by: Jiewen Tao, et al.
Published: (2021-01-01)

Vitamin D serum levels in women using contraception containing drospirenone – a preliminary study
by: Michał Ciebiera, et al.
Published: (2017-10-01)

Comparison of risks of thromboembolism of drospirenone-containing and nondrospirenone -containing combined oral contraceptive use: A meta-analysis
by: Wan-Lin Zhang, et al.
Published: (2021-01-01)

A Comparative Efficacy of Low-Dose Combined Oral Contraceptives Containing Desogestrel and Drospirenone in Premenstrual Symptoms
by: Jirath Wichianpitaya, et al.
Published: (2013-01-01)

CONTRACEPTION WITH DROSPIRENONE: EFFECT ON THE BODY WEIGHT AND SOME LIPID METABOLISM INDICATORS
by: A. A. Smetnik
Published: (2016-12-01)

A 1-year prospective, open-label, single-arm, multicenter, phase 3 trial of the contraceptive efficacy and safety of the oral progestin-only pill drospirenone 4 mg using a 24/4-day regimen
by: Thomas Kimble, et al.
Published: (2020-01-01)

EE-drospirenone-levomefolate calcium versus EE-drospirenone + folic acid: folate status during 24 weeks of treatment and over 20 weeks following treatment cessation
by: Diefenbach K, et al.
Published: (2013-04-01)

Preparation and Evaluation of Intravaginal Ring Containing Drospirenone
by: Ying Zhang, et al.
Published: (2013-01-01)

Efficacy and safety of combined ethinyl estradiol/drospirenone oral contraceptives in the treatment of acne
by: Jerry KL Tan, et al.
Published: (2009-11-01)

Burden of Menstrual Pain Measured by Heatmap Visualization of Daily Patient-Reported Data in Japanese Patients Treated with Ethinylestradiol/Drospirenone: A Randomized Controlled Study
by: Momoeda M, et al.
Published: (2020-03-01)

A comparison of combined oral contraceptives containing chlormadinone acetate versus drospirenone for the treatment of acne and dysmenorrhea: a randomized trial
by: Unnop Jaisamrarn, et al.
Published: (2018-04-01)

Simultaneous determination of ethinyl estradiol and drospirenone in oral contraceptive by high performance liquid chromatography
by: Viviane Benevenuti Silva, et al.
Published: (2013-09-01)

Efficacy, safety, and patient acceptability of the combined chlormadinone acetate-ethinylestradiol oral contraceptive
by: Serena Ferrari, et al.
Published: (2010-09-01)

Safety, efficacy and patient satisfaction with continuous daily administration of levonorgestrel/ethinylestradiol oral contraceptives
by: Giuseppe Benagiano, et al.
Published: (2009-04-01)

Does the presence of coexisting diseases modulate the effectiveness of a low-dose estrogen/progestin, ethinylestradiol/drospirenone combination tablet in dysmenorrhea? Reanalysis of two randomized studies in Japanese women
by: Momoeda M, et al.
Published: (2014-12-01)

Efficacy of cyclic and extended regimens of ethinylestradiol 0.02 mg ‐levonorgestrel 0.09 mg for dysmenorrhea: A placebo‐controlled, double‐blind, randomized trial
by: Tasuku Harada, et al.
Published: (2021-04-01)

Simultaneous total occlusion of two coronary arteries associated with use of drospirenone-ethinyl estradiol (oral contraceptive)
by: Hüsnü Atmaca, et al.
Published: (2018-01-01)

Satisfaction and compliance in hormonal contraception: the result of a multicentre clinical study on women's experience with the ethinylestradiol/norelgestromin contraceptive patch in Italy
by: Marelli Silvia, et al.
Published: (2009-06-01)

Determination of ethinylestradiol and levonorgestrel in oral contraceptives with HPLC methods with UV detection and UV/fluorescence detection
by: Zorica Arsova-Sarafinovska, et al.
Published: (2006-06-01)

Safety, efficacy, actions, and patient acceptability of drospirenone/ethinyl estradiol contraceptive pills in the treatment of premenstrual dysphoric disorder
by: Lesley L Breech, et al.
Published: (2009-08-01)

Efficacy of Drospirenone-Containing Hormone Replacement Therapy to Reduce Vasomotor Symptoms of Menopause
by: Dana A. Brown, et al.
Published: (2013-10-01)

17ß-estradiol (1 mg) i drospirenon (2 mg) w terapii hormonalnej okresu pomenopauzalnego
by: Grzegorz Stachowiak, et al.
Published: (2010-02-01)

Drospirenon v evolyutsiigormonal'noy kontratseptsii
by: Elena Anatol'evna Mezhevitinova, et al.
Published: (2011-04-01)